Marianna L. Ianzano

University of Bologna — Italy

Immunology and Microbiology · Life Sciences

12h-index653citations42works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(19), vaccines and immunoinformatics approaches(14), Monoclonal and Polyclonal Antibodies Research(12), HER2/EGFR in Cancer Research(8), Cancer Immunotherapy and Biomarkers(7)

Publications42 total

Supplementary Tables 1-4 from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Supplementary Tables 1-4 from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Data from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Supplementary Figure Legend from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Data from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Supplementary Methods from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Supplementary Methods from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Supplementary Figure 1 from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Supplementary Figure 1 from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Supplementary Figure Legend from <i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations
2023Open Access
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
Oncogenesis·2021· 20 citedOpen Access
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
Scientific Reports·2021· 10 citedOpen Access
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
Scientific Reports·2019· 74 citedOpen Access
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
Cancers·2019· 12 citedOpen Access
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
BMC Cancer·2019· 13 citedOpen Access
Abstract 716: A novel virus-like particle vaccine presenting HER-2 extracellular domain elicits strong immune responses against mammary carcinoma
Cancer Research·2018
Abstract 216: Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts
Cancer Research·2018· 1 cited
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
OncoImmunology·2018· 8 citedOpen Access
HER2 cancer vaccine optimization by combining Drosophila S2 insect cell manufacturing with a novel VLP-display technology
2018
Virus-like particle display of HER2 induces potent anti-cancer responses
OncoImmunology·2017· 120 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Arianna Palladini(41), Pier‐Luigi Lollini(41), Patrizia Nanni(41), Lorena Landuzzi(40), Giordano Nicoletti(39), Carla De Giovanni(36), Valentina Grosso(27), Stefania Croci(25), Annalisa Murgo(17), Valeria Stivani(17), Agnese Antognoli(17), Manuela Iezzi(12), Massimiliano Dall’Ora(12), Francesco Pappalardo(11), Santo Motta(11), Roberta Laranga(10), Tania Balboni(9), Veronica Giusti(9), Dario Ranieri(8), Augusto Amici(5)